Eur J Cancer 2022 Jun 24;172:85-95. Epub 2022 Jun 24.
CHU de Bordeaux, CIC1401, Service de Pharmacologie Médicale, Service de Biologie des tumeurs, Service des Maladies Respiratoires, F-33000 Pessac, France; Univ. Bordeaux, Inserm CIC1401, Inserm CR1219, Inserm U1035, F-33000 Bordeaux, France. Electronic address:
Background: Mutations in STK11/LKB1 gene present a negative impact on tumour immune microenvironment, especially with concomitant activating KRAS mutation. These recent data may explain a decreased response to immunotherapy treatment in STK11 mutant non-small cell lung cancer (NSCLC).
Objective: The primary objective is to evaluate, in a real-life setting, overall survival (OS) in patients with NSCLC according to the presence of STK11 mutation. Read More